Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | LIPC | P11150 | 14/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470957 | 0.81 | HPGD (0.62) | LIPCLIPGHPGDTSHRHTT | |
| SCHEMBL20972736 | 0.76 | LIPC (0.80) | LIPCLIPG | |
| SCHEMBL30076455 | 0.72 | KDM4E (0.54) | MEN1MAPTKMT2ANPSR1LIPG | |
| SCHEMBL28946486 | 0.72 | KDM4E (0.54) | MEN1MAPTKMT2ANPSR1LIPG | |
| SCHEMBL19709507 | 0.72 | LIPC (0.74) | LIPCLIPG | |
| SCHEMBL3089549 | 0.71 | HPGD (0.65) | MAPTHPGDTSHRHTTALDH1A1 | |
| SCHEMBL10049918 | 0.71 | HPGD (0.75) | MEN1MAPTKMT2AHPGDTSHR | |
| SCHEMBL31428953 | 0.69 | HPGD (0.63) | MEN1MAPTKMT2AHPGDTSHR | |
| SCHEMBL3089547 | 0.69 | HPGD (0.63) | MEN1MAPTKMT2AHPGDTSHR | |
| SCHEMBL12812023 | 0.69 | HPGD (0.62) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017214005-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, CEL | MEN1 4792/4885MAPT 4599/4885KMT2A 1810/4885 |
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | LIPG, LPL, CEL | MEN1 4792/4885MAPT 4599/4885KMT2A 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.